+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Familial Adenomatous Polyposis Treatment Market by Drug Class, Therapy Line, Route of Administration, Distribution Channel, End User - Global Forecast to 2030- Product Image
Familial Adenomatous Polyposis Treatment Market by Drug Class, Therapy Line, Route of Administration, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Familial Adenomatous Polyposis Treatment Market by Drug Class, Therapy Line, Route of Administration, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 197 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5967598
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Familial Adenomatous Polyposis Treatment Market is evolving rapidly, influenced by advances in targeted therapies, shifting regulatory landscapes, and ongoing pressures on patient care standards. Senior leaders require actionable intelligence to navigate complex therapy options, manage rising costs, and maintain competitiveness as the market redefines itself.

Market Snapshot: Familial Adenomatous Polyposis Treatment Market

The Familial Adenomatous Polyposis Treatment Market grew from USD 1.20 billion in 2024 to USD 1.29 billion in 2025. With an expected CAGR of 7.53%, the market is projected to reach USD 1.86 billion by 2030.

Scope & Segmentation

This research covers a comprehensive set of market segments, geographies, technologies, and leading companies, providing a detailed view for strategic planning and investment.

  • Drug Class: Gene Therapy, Monoclonal Antibodies, mTOR Inhibitors, Nonsteroidal Anti-Inflammatory Drugs (Aspirin, Indomethacin, Sulindac), Selective COX-2 Inhibitors (Celecoxib, Etoricoxib, Parecoxib)
  • Therapy Line: Adjuvant, First Line, Maintenance, Second Line, Third Line
  • Route Of Administration: Oral (Capsule, Tablet), Parenteral (Intravenous, Subcutaneous), Topical (Cream, Gel)
  • Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
  • End User: Home Care, Hospitals, Specialty Clinics
  • Region: Americas (United States—California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada; Mexico; Brazil; Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Key Companies: Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Viatris Inc., Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy's Laboratories Limited, Cipla Limited, Zydus Lifesciences Limited, Aurobindo Pharma Limited

Key Takeaways for Senior Decision-Makers

  • Significant diversification in drug classes is steering the market toward tailored, precision-based patient care models.
  • Gene editing and monoclonal antibody advancements are emerging alongside optimized small-molecule strategies, broadening the range of available therapies.
  • Healthcare providers are balancing traditional chemoprevention with newer molecular and immunomodulatory tools, adjusting to fast-changing clinical pathways.
  • Growth in digital health integration, including remote monitoring and patient engagement platforms, is supporting adherence and evidence collection in maintenance regimens.
  • Regional differences in regulation, funding, and distribution impact adoption rates, favoring agile market entrants able to localize offerings.
  • Strategic collaborations between established pharmaceutical leaders and biotech innovators are accelerating the development and reach of next-generation therapies.

Tariff Impact

The implementation of US tariff measures in 2025 has increased input costs for gene therapy vectors and active pharmaceutical ingredients. Manufacturers faced additional expense burdens across both viral and nonviral platforms, prompting a focus on domestic supply resilience and nearshoring. Resultant price adjustments are influencing budgets, adoption rates, and creating the need for robust payer negotiations. Strategic sourcing from tariff-exempt locations and investment in efficient modalities are now central to mitigating market disruption.

Methodology & Data Sources

Insights are derived from a rigorous analysis of primary and secondary sources. In-depth interviews with clinical leaders and industry executives supplement data from market surveys. Secondary reviews of peer-reviewed articles, regulatory filings, patent resources, and corporate disclosures provide further context. Advanced analytics, including demand modeling and scenario assessment, underpin all findings.

Why This Report Matters

  • Clarifies critical treatment trends and technology trajectories shaping the Familial Adenomatous Polyposis Treatment Market.
  • Enables informed decision-making by detailing regional, clinical, and economic factors that directly influence competitive positioning and investment strategy.
  • Supports future-proofing with a thorough examination of evolving payer requirements, digital innovation uptake, and supply chain considerations.

Conclusion

Senior leaders leveraging these insights can anticipate changes, align resources, and strengthen market positioning. Rigorous and data-driven, the report enables companies to confidently chart growth strategies and improve patient care outcomes in a dynamic global environment.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing concerns related to genetic disorders among populations and the need for effective treatment options
5.1.1.2. Favorable government initiatives and reimbursement policies for colorectal cancer
5.1.2. Restraints
5.1.2.1. Strict governments regulations for FAP drugs and cases of product recalls
5.1.3. Opportunities
5.1.3.1. Rapid pace of technological innovation in genetic testing and drug delivery system
5.1.3.2. Investment in the research and development of new drugs and less invasive surgical techniqe
5.1.4. Challenges
5.1.4.1. Risk of significant side effects associated with the FAP medicines
5.2. Market Segmentation Analysis
5.2.1. Type: Growing preference for icosapent and aspirin as an anti-inflammatory medications in Familial Adenomatous Polyposis (FAP) treatment
5.2.2. End-Users: Widening availability of Familial Adenomatous Polyposis treatment options through hospitals and diagnostic centers
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Familial Adenomatous Polyposis Treatment Market, by Type
6.1. Introduction
6.2. Aspirin
6.3. CEQ-508
6.4. Eflornithine Hydrochloride
6.5. Icosapent
7. Familial Adenomatous Polyposis Treatment Market, by End-Users
7.1. Introduction
7.2. Clinics & Hospitals
7.3. Diagnostic Centres
7.4. Home Healthcare
8. Familial Adenomatous Polyposis Treatment Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacy
8.3. Retail Pharmacy
9. Americas Familial Adenomatous Polyposis Treatment Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Familial Adenomatous Polyposis Treatment Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Familial Adenomatous Polyposis Treatment Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. Breakthrough Treatment for Desmoid Tumors Receives FDA Approval
12.3.2. FDA Grants Orphan-Drug Designation to Therapyx's FAPXIL for Familial Adenomatous Polyposis Treatment
12.3.3. Groundbreaking Clinical Trial for Familial Adenomatous Polyposis Receives FDA Go-Ahead
12.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
FIGURE 9. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 11. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET DYNAMICS
TABLE 7. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ASPIRIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY CEQ-508, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY EFLORNITHINE HYDROCHLORIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ICOSAPENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY CLINICS & HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DIAGNOSTIC CENTRES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 23. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 24. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 25. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 26. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 27. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 28. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 29. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 30. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 31. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 32. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 33. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 34. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 39. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 40. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 42. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 43. AUSTRALIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 44. AUSTRALIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 45. AUSTRALIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 46. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 47. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 48. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. INDIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 50. INDIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 51. INDIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 52. INDONESIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 53. INDONESIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 54. INDONESIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. JAPAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 56. JAPAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 57. JAPAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 58. MALAYSIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 59. MALAYSIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 60. MALAYSIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. PHILIPPINES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 62. PHILIPPINES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 63. PHILIPPINES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. SINGAPORE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 65. SINGAPORE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 66. SINGAPORE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. SOUTH KOREA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 68. SOUTH KOREA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 69. SOUTH KOREA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. TAIWAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 71. TAIWAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 72. TAIWAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. THAILAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 74. THAILAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 75. THAILAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. VIETNAM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 77. VIETNAM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 78. VIETNAM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 83. DENMARK FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 84. DENMARK FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 85. DENMARK FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. EGYPT FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 87. EGYPT FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 88. EGYPT FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. FINLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 90. FINLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 91. FINLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. FRANCE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 93. FRANCE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 94. FRANCE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 96. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 97. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. ISRAEL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 99. ISRAEL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 100. ISRAEL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. ITALY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 102. ITALY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 103. ITALY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. NETHERLANDS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 105. NETHERLANDS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 106. NETHERLANDS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. NIGERIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 108. NIGERIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 109. NIGERIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. NORWAY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 111. NORWAY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 112. NORWAY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. POLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 114. POLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 115. POLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. QATAR FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 117. QATAR FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 118. QATAR FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 123. SAUDI ARABIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 124. SAUDI ARABIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 126. SOUTH AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 127. SOUTH AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. SPAIN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 129. SPAIN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 130. SPAIN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 132. SWEDEN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 133. SWEDEN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. SWITZERLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 135. SWITZERLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 136. SWITZERLAND FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. TURKEY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 138. TURKEY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 139. TURKEY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
TABLE 147. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Familial Adenomatous Polyposis Treatment market report include:
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Viatris Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Limited
  • Dr. Reddy's Laboratories Limited
  • Cipla Limited
  • Zydus Lifesciences Limited
  • Aurobindo Pharma Limited

Table Information

Report AttributeDetails
No. of Pages197
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.29 Billion
Forecasted Market Value ( USD ) by 2030 $ 1.86 Billion
Compound Annual Growth Rate7.5%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Familial Adenomatous Polyposis - Pipeline Insight, 2025 - Product Image

Familial Adenomatous Polyposis - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Familial Adenomatous Polyposis Coli - Pipeline Insight, 2025 - Product Image

Familial Adenomatous Polyposis Coli - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Colorectal Cancer Diagnosis and Therapeutic Updates - Product Image

Colorectal Cancer Diagnosis and Therapeutic Updates

  • Book
Gardner Syndrome Treatment Market Report 2025 - Product Image

Gardner Syndrome Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Gardner Syndrome Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Gardner Syndrome Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From

About the Familial Adenomatous Polyposis Drug Market

Familial Adenomatous Polyposis (FAP) is a rare genetic disorder that causes the formation of numerous polyps in the colon. These polyps can become cancerous if left untreated. As such, drugs used to treat FAP are important in the treatment of colon cancer. These drugs are typically targeted therapies, which are designed to specifically target the genetic mutation that causes FAP. Commonly used drugs include bevacizumab, cetuximab, and panitumumab. These drugs are used in combination with other treatments such as chemotherapy and radiation therapy. The Familial Adenomatous Polyposis Drug market is a small but growing market. It is driven by the increasing prevalence of FAP and the need for effective treatments. The market is expected to grow in the coming years as new treatments are developed and approved. Some companies in the market include Roche, Merck, Pfizer, and Bristol-Myers Squibb. These companies are involved in the development and marketing of drugs used to treat FAP. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.